Table 2.
Changes of hormonal, metabolic and anthropometric parameters.
| Parameters | MET (N=25) | COM (N=27) | aP | bP | ||||
|---|---|---|---|---|---|---|---|---|
| Baseline | 4 weeks | 12 weeks | Baseline | 4 weeks | 12 weeks | |||
| Regular menstrual cycles (%,n) | 0%,0 | 52.00%,13* | 88.00%,22** | 0%,0 | 77.78%,21** | 92.59%,25** | 0.08 | 0.662 |
| Weight (kg) | 76.50 ± 12.44 | 74.10 ± 12.45** | 71.44 ± 11.50** | 79.09 ± 8.46 | 73.26 ± 7.71** | 69.96 ± 7.23** | 0.773 | 0.586 |
| BMI (kg/m2) | 28.80 ± 4.25 | 27.89 ± 4.21** | 26.88 ± 3.76** | 29.69 ± 3.44 | 27.49 ± 3.03** | 26.24± 2.75** | 0.69 | 0.485 |
| AG (cm) | 91.96 ± 12.09 | 87.82 ± 11.79** | 83.40 ± 12.42** | 95.69 ± 8.94 | 90.28 ± 8.20** | 86.30 ± 8.25** | 0.384 | 0.331 |
| FG (mmol/L) | 5.48 ± 0.52 | 5.20 ± 0.32* | 5.70 ± 0.93 | 5.05 ± 0.40** | 0.222 | |||
| FINS (μU/mL) | 18.13 ± 11.73 | 12.87 ± 7.93** | 18.89 ± 7.15 | 11.60 ± 4.22** | 0.577 | |||
| HOMA-IR | 4.53 ± 3.07 | 2.86 ± 2.05** | 4.85 ± 2.09 | 2.62 ± 1.05** | 0.677 | |||
| AUCglu (mmol/L*min) | 1009.00 ± 109.00 | 1007.00 ± 89.43 | 1135.00 ± 144.50 | 972.70 ± 135.70 | 0.687 | |||
| AUCins (mU/L*min) | 13305.00 ± 4458.00 | 11820.00 ± 3867.00 | 13223.00 ± 3817.00 | 8964.00 ± 2919.00 | 0.253 | |||
| AUCins/AUCglu | 11.31 ± 7.17 | 10.14 ± 6.84 | 11.22 ± 7.11 | 8.39 ± 5.50 | 0.387 | |||
| E2 (pg/mL) | 35.00 (27.49-40.50) | 46.00 (35.33-66.50)* | 71.10 (48.37-120.00)** | 40.00 (32.00-67.00) | 54.00 (41.00-99.00)** | 90.00 (58.00-184.00)** | 0.053 | 0.181 |
| LH (mIU/mL) | 11.97 ± 4.20 | 12.08 ± 6.47 | 9.77 ± 5.81 | 12.09 ± 5.26 | 9.54 ± 4.52 | 6.61 ± 4.72** | 0.105 | 0.036 |
| FSH (mIU/mL) | 6.03 ± 1.48 | 5.91 ± 1.72 | 5.28 ± 2.11 | 6.22 ± 1.44 | 5.15 ± 1.93** | 4.42 ± 2.59** | 0.14 | 0.197 |
| LH/FSH | 2.12 ± 0.97 | 2.03 ± 1.02 | 1.91 ± 0.86 | 2.04 ± 0.98 | 1.94 ± 0.80 | 1.59 ± 0.95 | 0.725 | 0.215 |
| PRL (ng/mL) | 10.81 ± 4.21 | 10.80 ± 4.52 | 13.07 ± 5.77* | 10.21 ± 3.66 | 10.65 ± 4.64 | 12.91 ± 4.97** | 0.903 | 0.914 |
| Prog (ng/mL) | 0.50 (0.29-0.75) | 0.45 (0.29-1.14) | 0.54 (0.31-1.72) | 0.42 (0.22-0.56) | 0.53 (0.39-1.21) | 1.08 (0.52-10.61)** | 0.272 | 0.020 |
| TT (ng/mL) | 0.84 ± 0.25 | 0.81 ± 0.35 | 0.79 ± 0.31 | 0.79 ± 0.20 | 0.70 ± 0.24 | 0.62 ± 0.24** | 0.163 | 0.032 |
| SHBG (nmol/L) | 18.10 (11.75-24.10) | 19.90 (13.90-27.45) | 22.40 (15.25-34.60)** | 18.80 (14.90-21.90) | 22.10 (17.10-26.90)* | 27.00 (22.60-44.90)** | 0.395 | 0.018 |
| FAI (%) | 15.62 (10.99-26.53) | 14.22 (6.85-21.85) | 12.72 (6.40-17.71)* | 13.94 (11.93-19.40) | 9.55 (5.78-17.01) | 7.06 (3.90-10.19)** | 0.104 | 0.004 |
BMI, body mass index; AG, abdominal girth; FG, fasting glucose; FINS, fasting insulin; HOMA-IR, homeostasis model assessment-insulin resistance; AUCglu, area under the curve (AUC) for glucose; AUCins, AUC for insulin; E2, estradiol; LH, luteinizing hormone; FSH, follicle-stimulating hormone; PRL, prolactin; Prog, progesterone; TT, total testosterone; SHBG, sex hormone-binding globulin; FAI, free androgen index. Results are expressed as mean ± SD or median (25th–75th percentile). *P < 0.05, post-treatment vs. baseline; **P < 0.01, post-treatment vs. baseline; aP < 0.01, COM vs. MET at the 4th week; bP < 0.01, COM vs. MET at the 12th week. Statistically significant results are presented in bold.